<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Diagn Pathol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Diagn Pathol</journal-id>
      <journal-title-group>
        <journal-title>Diagnostic Pathology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1746-1596</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26445485</article-id>
      <article-id pub-id-type="pmc">4596369</article-id>
      <article-id pub-id-type="publisher-id">421</article-id>
      <article-id pub-id-type="doi">10.1186/s13000-015-0421-y</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Spontaneous regression of plasmablastic lymphoma in an elderly human immunodeficiency virus (HIV)-negative patient</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Igawa</surname>
            <given-names>Takuro</given-names>
          </name>
          <address>
            <email>me19075@s.okayama-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Sato</surname>
            <given-names>Yasuharu</given-names>
          </name>
          <address>
            <phone>+81-86-235-7150</phone>
            <email>satou-y@okayama-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kawai</surname>
            <given-names>Hotaka</given-names>
          </name>
          <address>
            <email>de18018@s.okayama-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kondo</surname>
            <given-names>Eisei</given-names>
          </name>
          <address>
            <email>eisei-k@md.okayama-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takeuchi</surname>
            <given-names>Mai</given-names>
          </name>
          <address>
            <email>maitake@okayama-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miyata-Takata</surname>
            <given-names>Tomoko</given-names>
          </name>
          <address>
            <email>tomoko-ecl@umin.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takata</surname>
            <given-names>Katsuyoshi</given-names>
          </name>
          <address>
            <email>katsuyoshi.t@h5.dion.ne.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yoshino</surname>
            <given-names>Tadashi</given-names>
          </name>
          <address>
            <email>yoshino@md.okayama-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan </aff>
        <aff id="Aff2"><label/>Division of Pathophysiology, Okayama University Graduate School of Health Sciences, 2-5-1 Shikata-cho, Okayama, 700-8558 Japan </aff>
        <aff id="Aff3"><label/>Department of Oral Pathology and Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan </aff>
        <aff id="Aff4"><label/>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>6</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>6</day>
        <month>10</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>10</volume>
      <elocation-id>183</elocation-id>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>8</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>10</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Igawa et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Plasmablastic lymphoma (PBL) is an aggressive lymphoma commonly associated with human immunodeficiency virus (HIV) infection. Herein we describe a rare case of PBL that spontaneously regressed. An 80-year-old man was referred to our hospital owing to an exophytic gingival tumor in the right maxillary second molar region. He had no significant past medical history, and a screening test for HIV was negative. Imaging showed that the tumor measured 26&#x2009;&#xD7;&#x2009;23&#x2009;&#xD7;&#x2009;16&#xA0;mm and was confined in the alveolar bone. The tumor was histologically comprised of highly proliferative immunoblastic cells positive for CD138 and Epstein-Barr virus (EBV)-encoded RNA. Monoclonal IgH chain gene rearrangement was detected via polymerase chain reaction. After biopsy and diagnosis of PBL, the tumor began to decrease in size and had apparently disappeared at the time of surgery. There was no histological evidence of a residual lesion in the surgical specimen. In conclusion, a minority of immunosenescence-associated PBLs in the elderly should be recognized as a unique clinicopathological entity distinct from common aggressive PBL.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Plasmablastic lymphoma</kwd>
        <kwd>Spontaneous regression</kwd>
        <kwd>Immunosenescence</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>Plasmablastic lymphoma (PBL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL), with a median overall survival time of less than one year, initially documented in 1997 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. PBL most commonly occurs in the oral cavity of human immunodeficiency virus (HIV)-positive individuals [<xref ref-type="bibr" rid="CR2">2</xref>]. It is also associated with other immunodeficiency states, such as iatrogenic immunosuppression due to administration of immunosuppressive agents or immunosenescence in elderly adults [<xref ref-type="bibr" rid="CR2">2</xref>]. Although there seems to be no significant difference in the prognosis of HIV-positive and HIV-negative PBLs [<xref ref-type="bibr" rid="CR2">2</xref>], rare PBLs in elderly HIV-negative patients without other known immunodeficiency conditions have recently been shown to possess unique clinicopathological features including relatively indolent clinical behavior [<xref ref-type="bibr" rid="CR3">3</xref>]. It has been proposed that this age-related type of PBL be categorized as PBL of the elderly (PBL-E) [<xref ref-type="bibr" rid="CR3">3</xref>]. Epstein-Barr virus (EBV) infection has been observed in all cases of PBL-E [<xref ref-type="bibr" rid="CR3">3</xref>], compared with 50 to 75&#xA0;% of PBL cases associated with the other immunodeficiency conditions [<xref ref-type="bibr" rid="CR2">2</xref>].</p>
      <p>Spontaneous regression of low-grade lymphoma reportedly occurs in about 10&#xA0;% of cases [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], whereas spontaneous regression of aggressive lymphoma after biopsy has rarely been observed [<xref ref-type="bibr" rid="CR6">6</xref>]. Spontaneous regression of DLBCL in patients with rheumatoid arthritis taking methotrexate after immunosuppressant withdrawal has recently been reported [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
      <p>We herein describe a rare case of PBL-E that spontaneously regressed in the absence of any anti-neoplastic treatment.</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>An 80-year-old man was referred to our hospital owing to rapid growth of a gingival tumor in the right maxillary second molar region. He had suffered from repeated gingival swelling of this region for 8&#xA0;months before his visit. Following a diagnosis of apical periodontitis, his right maxillary second molar was extracted 6&#xA0;weeks before his visit. After an additional mucosal curettage to treat unsuccessful wound healing, the gingiva at the extraction site began to rapidly grow in size. The patient had no significant past medical history including autoimmune diseases and had not taken any immunosuppressive medication.</p>
      <p>A physical examination revealed an exophytic gingival tumor in the right maxillary second molar (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1a</xref>). This soft elastic tumor was well circumscribed and bled easily. Computed tomography showed that the tumor measured 26&#x2009;&#xD7;&#x2009;23&#x2009;&#xD7;&#x2009;16&#xA0;mm and was confined in the alveolar bone. Progression of the tumor to the maxillary antrum was not observed, nor was lymph node swelling. <sup>18</sup>F-fludeoxyglucose positron emission tomography (FDG-PET) showed elevated FDG uptake in the right maxilla with a maximum standardized uptake value of 29.29 (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1b</xref>). Abnormal FDG uptake at other sites was not noted. Serum levels of lactate dehydrogenase (208&#xA0;IU/L) and soluble interleukin-2 receptor (177 U/mL) were normal, and a screening test for HIV was negative. Serological tests for EBV were also performed (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Clinical photographs and imaging data. Clinical photographs (<bold>a</bold>, <bold>c</bold>) and positron emission tomography/computed tomography (PET/CT) imaging (<bold>b</bold>, <bold>d</bold>) of the lesion. Initial presentation (<bold>a</bold>, <bold>b</bold>), 40&#xA0;days after biopsy when surgery was performed (<bold>c</bold>), and 102&#xA0;days after biopsy (<bold>d</bold>). The exophytic tumor had clinically disappeared</p></caption><graphic xlink:href="13000_2015_421_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Serological tests for EBV and real-time PCR for EBV-DNA in whole blood</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>At biopsy</th><th>Four days after surgery<sup>a</sup>
</th><th>Reference (range)</th></tr></thead><tbody><tr><td>VCA-IgG (titer)</td><td>320</td><td>80</td><td>&lt;10</td></tr><tr><td>VCA-IgA (titer)</td><td>&lt;10</td><td>NA</td><td>&lt;10</td></tr><tr><td>VCA-IgM (titer)</td><td>&lt;10</td><td>&lt;10</td><td>&lt;10</td></tr><tr><td>EA-DR-IgG (titer)</td><td>&lt;10</td><td>NA</td><td>&lt;10</td></tr><tr><td>EA-DR-IgA (titer)</td><td>&lt;10</td><td>NA</td><td>&lt;10</td></tr><tr><td>EBNA (titer)</td><td>20</td><td>20</td><td>&lt;10</td></tr><tr><td>EBV-DNA (copies/&#x3BC;gDNA)</td><td>NA</td><td>3.7 x 10^2</td><td>&lt;1&#x2009;&#xD7;&#x2009;10^2.5</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Day 44 after biopsy</p><p>
<italic>VCA</italic> viral capsid antigen<italic>, EA-DR</italic> early antigen-diffuse and restrict complex, <italic>EBNA</italic> Epstein-Barr virus nuclear antigen, <italic>EBV</italic> Epstein-Barr virus, <italic>NA</italic> not available</p></table-wrap-foot></table-wrap></p>
      <p>A biopsy of the lesion showed a solid tumor with an ulcertic surface (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2a</xref>). The tumor was characterized by monomorphic neoplastic proliferation of large plasmacytoid and immunoblastic cells with prominent nucleoli (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2b</xref>). Necrosis and giant cells with features similar to those of Hodgkin and Reed/Sternberg cells were not observed. Immunohistochemical immunophenotyping analysis showed that the neoplastic cells were positive for LCA and CD138 and negative for CD20, CD79a, PAX5, CD3, CD5, CD10, CD15, CD56, ALK, LMP1, and EBNA2 (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2c, d</xref>). CD30 expression was not determined. Forty percent of the tumor cells expressed c-Myc, and the Ki-67 labeling index was &gt;80&#xA0;% (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2e</xref>). As determined via <italic>in situ</italic> hybridization, neoplastic cells were EBV-encoded RNA (EBER)-positive (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2f</xref>). Although cytoplasmic &#x3BA; and &#x3BB; light chains were not detected via <italic>in situ</italic> hybridization (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2g, h</xref>), clonal IgH chain gene rearrangement was detected via polymerase chain reaction (PCR) (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2i</xref>). Because the patient had no immunosuppressive condition other than advanced age, he was diagnosed with PBL-E, and surgical excision was scheduled.<fig id="Fig2"><label>Fig. 2</label><caption><p>Histology and polymerase chain reaction (PCR) analysis of the lesion at initial presentation. Hematoxylin and eosin staining (<bold>a</bold>, <bold>b</bold>). (<bold>a</bold>) Original magnification, &#xD7;100. (b) Original magnification, &#xD7;400. Immunohistochemistry for CD20 (<bold>c</bold>), CD138 (<bold>d</bold>), and Ki-67 (<bold>e</bold>) (original magnification, &#xD7;400). <italic>In situ</italic> hybridization analyses for Epstein-Barr virus-encoded RNA (EBER) (<bold>f</bold>) and immunoglobulin &#x3BA; (<bold>g</bold>) and &#x3BB; (<bold>h</bold>) light chain (original magnification, &#xD7;400). PCR analysis for immunoglobulin heavy chain rearrangements (<bold>i</bold>). The lesion was a solid tumor with an ulcertic surface (<bold>a</bold>). Immunoblastic cells with prominent nucleoli (<bold>b</bold>) were negative for CD20 (<bold>c</bold>) but positive for CD138 and EBER (<bold>d</bold>, <bold>f</bold>) with a high Ki-67 index (e). Cytoplasmic immunoglobulin light chain was absent (<bold>e</bold>, <bold>g</bold>). Monoclonal IgH chain gene rearrangement was demonstrated (<bold>i</bold>)</p></caption><graphic xlink:href="13000_2015_421_Fig2_HTML" id="MO2"/></fig></p>
      <p>After the biopsy, however, the tumor began to decrease in size. Surgical excision was performed 40&#xA0;days after the biopsy, although the exophytic tumor had apparently disappeared (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1c</xref>). A surgical specimen showed infiltration of CD138-positive plasma cells and polymorphic inflammatory cells, including numerous foamy macrophages (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3a, b</xref>). The plasma cells expressed cytoplasmic immunoglobulins (&#x3BA; and &#x3BB; light chain) with no light chain restriction, and the results of EBER <italic>in situ</italic> hybridization were negative (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3c&#x2013;e</xref>). There was no evidence of a residual neoplastic lesion.<fig id="Fig3"><label>Fig. 3</label><caption><p>Histology of the surgical specimen. Hematoxylin and eosin staining (original magnification, &#xD7;200) (<bold>a</bold>). Immunohistochemical CD138 staining (original magnification, &#xD7;400) (<bold>b</bold>). <italic>In situ</italic> hybridization analyses for Epstein-Barr virus-encoded RNA (EBER) (<bold>c</bold>), and immunoglobulin &#x3BA; (<bold>d</bold>) and &#x3BB; (<bold>e</bold>) light chain (original magnification, &#xD7;400). Plasma cell infiltration was observed along with polymorphic inflammatory cells including numerous foam cells (<bold>a</bold>, <bold>b</bold>). The plasma cells were negative for EBER but expressed cytoplasmic immunoglobulin &#x3BA; and &#x3BB; light chain</p></caption><graphic xlink:href="13000_2015_421_Fig3_HTML" id="MO3"/></fig></p>
      <p>Serological testing for EBV was performed 4&#xA0;days after surgery, and EBV-DNA was detected in whole blood via real-time PCR (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). FDG-PET imaging 102&#xA0;days after the biopsy showed no abnormal FDG uptake (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1d</xref>), suggesting that the neoplastic lesion had clinically disappeared completely. The patient has thus far been followed-up for 5&#xA0;months with no sign of relapse.</p>
    </sec>
    <sec id="Sec3" sec-type="conclusion">
      <title>Conclusions</title>
      <p>PBL is histologically highly aggressive with a high mitotic index [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. However, the plasmablastic tumor cells in this case completely disappeared in the absence of any anti-tumor treatment after biopsy. A previous report described five cases of age-related EBV-positive mucocutaneous ulcers (EBV-MCUs) that spontaneously regressed without treatment (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR8">8</xref>]. Interestingly, the PBL-E in our case shares clinical characteristics with these EBV-MCUs, such as old age, mucosa site, a well-circumscribed lesion, ulcer formation, EBV infection, Stage I disease, and a self-limited clinical course [<xref ref-type="bibr" rid="CR8">8</xref>]. EBV-MCUs are associated with immunosuppressive conditions, such as immunosenescence due to aging, and are considered an indolent EBV-induced lymphoproliferative disorder (LPD) rather than overt lymphomas [<xref ref-type="bibr" rid="CR8">8</xref>]. Thus far, they have not been associated with HIV infection, and histologically, they contain polymorphous B-cells, including plasmacytoid apoptotic cells and immunoblasts, showing plasmacytic differentiation [<xref ref-type="bibr" rid="CR8">8</xref>].<table-wrap id="Tab2"><label>Table 2</label><caption><p>Localized indolent EBV-associated lymphoproliferative disorder/lymphoma in the eldery</p></caption><table frame="hsides" rules="groups"><thead><tr><th>No</th><th>Age/Sex</th><th>Site</th><th>Pathologic diagnosis</th><th>HIV infection</th><th>Treatment</th><th>Outcome</th><th>Follow-up(months)</th><th>IGH/MYC</th><th>Reference No. (case No.)</th></tr></thead><tbody><tr><td>1</td><td>80/M</td><td>Gingiva</td><td>PBL-E</td><td>-</td><td>None</td><td>SR</td><td>Alive (8)</td><td>N</td><td>Present case</td></tr><tr><td>2</td><td>79/M</td><td>Skin of check</td><td>EBV-MCU</td><td>-</td><td>None</td><td>SR</td><td>DNED (25)</td><td>NA</td><td>8 (1)</td></tr><tr><td>3</td><td>82/M</td><td>Lip, Skin</td><td>EBV-MCU</td><td>-</td><td>None</td><td>SR</td><td>NA</td><td>NA</td><td>8 (2)</td></tr><tr><td>4</td><td>76/M</td><td>Tongue</td><td>EBV-MCU</td><td>-</td><td>None</td><td>SR</td><td>Alive (12)</td><td>NA</td><td>8 (7)</td></tr><tr><td>5</td><td>68/F</td><td>Tongue</td><td>EBV-MCU</td><td>-</td><td>None</td><td>SR</td><td>Alive (36)</td><td>NA</td><td>8 (13)</td></tr><tr><td>6</td><td>88/M</td><td>Skin of chest</td><td>EBV-MCU</td><td>-</td><td>None</td><td>SR</td><td>Alive (3)</td><td>NA</td><td>8 (16)</td></tr><tr><td>7</td><td>64/M</td><td>Nasal cavity</td><td>PBL-E</td><td>-</td><td>CHOP&#x2009;+&#x2009;RT</td><td>CR</td><td>Alive (55)</td><td>N</td><td>3 (4)</td></tr><tr><td>8</td><td>70/M</td><td>Gingiva</td><td>PBL-E</td><td>-</td><td>CHOP</td><td>CR</td><td>Alive (23)</td><td>R</td><td>3 (6)</td></tr><tr><td>9</td><td>60/M</td><td>Nasal cavity</td><td>PBL-E</td><td>-</td><td>CHOP</td><td>Under therapy</td><td>Alive (1)</td><td>N</td><td>3 (8)</td></tr></tbody></table><table-wrap-foot><p>
<italic>M</italic> male, <italic>F</italic> female, <italic>PBL-E</italic> plasmablastic lymphoma of the elderly, <italic>EBV-MCU</italic> Epstein-Barr virus-positie mucocutaneous ulcer, <italic>HIV</italic> human immunodeficiency virus, <italic>CHOP</italic> cyclophosphamide-adriamycin-vincristine-prednisone, <italic>RT</italic> radiotherapy, <italic>SR</italic> spontaneous regression, CR complete response, <italic>DNED</italic> died no evidence of disease, <italic>NA</italic> not available, <italic>N</italic> negative, <italic>R</italic> rearrangement</p></table-wrap-foot></table-wrap></p>
      <p>Because the PBL-E in our case closely resembles an EBV-MCU, we suggest that it should be considered as an indolent EBV-associated B-cell LPD rather than a common aggressive PBL. It would, however, be considered an atypical EBV-associated LPD owing to its distinctive morphology and immunophenotype. Monomorphically proliferating large lymphoid cells expressing B cell antigens such as CD20 and CD79a are often seen in EBV-associated LPDs [<xref ref-type="bibr" rid="CR9">9</xref>]. In contrast, the large neoplastic cells observed in our case, which had abundant cytoplasm and prominent nucleoli, expressed CD138 but not CD20 or CD79a. Although necrosis and giant cells resembling Hodgkin and Reed/Sternberg cells are often observed in EBV-associated LPDs, they were not observed in the PBL-E in our case [<xref ref-type="bibr" rid="CR9">9</xref>].</p>
      <p>Similar to our study, a previous report indicated that indolent Stage I PBL-E tumors in three elderly patients had clinical features resembling those of EBV-MCUs (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR3">3</xref>]. Because these patients received multi-agent chemotherapy soon after diagnosis, it is not known whether their tumors would have regressed spontaneously. To our knowledge, we are the first to report spontaneous regression of a PBL-E. More studies are required to determine the biological features of PBL-E tumors with characteristics similar to those seen in indolent EBV-associated LPDs.</p>
      <p>EBV inhibits apoptosis and promotes pathogenesis in EBV-associated LPDs [<xref ref-type="bibr" rid="CR8">8</xref>]. Although the latency status of EBV in EBV-associated LPDs is usually type II or III, the EBV latency status in our case was type I, in agreement with a previous report of PBL-E [<xref ref-type="bibr" rid="CR3">3</xref>]. One possible mechanism of the spontaneous regression of the PBL-E is mobilization of the immune system against EBV. In our case, the viral capsid antigen-IgG titer in serum decreased from 1:320 before regression to 1:80 after regression. This change, however, most likely had no significant effect on regression because both titers were within the low range.</p>
      <p><italic>MYC</italic> translocation is a negative prognostic factor for and contributes to the pathogenesis of PBLs [<xref ref-type="bibr" rid="CR2">2</xref>] including PBL-E [<xref ref-type="bibr" rid="CR3">3</xref>]. In our case, however, the c-Myc protein was not highly expressed, and <italic>IgH/MYC</italic> translocations were not detected via fluorescence in-situ hybridization. The absence of this translocation may account at least in part for the indolent clinical course of the PBL-E in our case.</p>
      <p>In contrast to our case, three previously reported cases of PBL showing spontaneous regression were clearly associated with a specific immunodeficiency (e.g., HIV infection [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] and methotrexate administration [<xref ref-type="bibr" rid="CR12">12</xref>]). The spontaneous regression in these cases may be related to the patient&#x2019;s restoration of immune function secondary to anti-HIV treatment or reduced dosage of an immunosuppressive agent. Therefore, the mechanisms underlying the spontaneous regression in our case may differ from those in these previous cases.</p>
      <p>In conclusion, PBL-E can partially follow, albeit rarely, a self-limited clinical course without anti-neoplastic therapy. Only a few PBLs associated with immunosenescence have characteristics similar to those of indolent EBV-associated LPDs and should be recognized as a unique clinicopathological entity distinct from common aggressive PBL.</p>
    </sec>
    <sec id="Sec4">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this report and any accompanying images.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>PBL</term>
          <def>
            <p>Plasmablastic lymphoma</p>
          </def>
        </def-item>
        <def-item>
          <term>DLBCL</term>
          <def>
            <p>Diffuse large B-cell lymphoma</p>
          </def>
        </def-item>
        <def-item>
          <term>HIV</term>
          <def>
            <p>Human immunodeficiency virus</p>
          </def>
        </def-item>
        <def-item>
          <term>PBL-E</term>
          <def>
            <p>Plasmablastic lymphoma of the elderly</p>
          </def>
        </def-item>
        <def-item>
          <term>EBV</term>
          <def>
            <p>Epstein-Barr virus</p>
          </def>
        </def-item>
        <def-item>
          <term>FDG-PET</term>
          <def>
            <p><sup>18</sup>F-fludeoxyglucose positron emission tomography</p>
          </def>
        </def-item>
        <def-item>
          <term>EBER</term>
          <def>
            <p>Epstein-Barr virus-encoded RNA</p>
          </def>
        </def-item>
        <def-item>
          <term>PCR</term>
          <def>
            <p>Polymerase chain reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>EBV-MCU</term>
          <def>
            <p>Epstein-Barr virus-positive mucocutaneous ulcer</p>
          </def>
        </def-item>
        <def-item>
          <term>LPD</term>
          <def>
            <p>Lymphoproliferative disorder</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors report no potential conflicts of interest.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>YS and TI conceived and designed the study. YS, TI, EK, MT, TM, KT, and TY analyzed the data. TI, YS, and HK wrote the manuscript. All authors read and approved the final manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>This work was supported in part by a Grant for Intractable Diseases (IgG4-related disease research program) from the Ministry of Health, Labor and Welfare in Japan.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Delecluse</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Anagnostopoulos</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dallenbach</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hummel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Marafioti</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>U</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasmablastic lymphoma of the oral cavity: a new entity associated with the human immunodeficiency virus infection</article-title>
          <source>Blood</source>
          <year>1997</year>
          <volume>89</volume>
          <issue>4</issue>
          <fpage>1413</fpage>
          <lpage>20</lpage>
          <pub-id pub-id-type="pmid">9028965</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Castillo</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Bibas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Miranda</surname>
              <given-names>RN</given-names>
            </name>
          </person-group>
          <article-title>The biology and treatment of plasmablastic lymphoma</article-title>
          <source>Blood</source>
          <year>2015</year>
          <volume>125</volume>
          <issue>15</issue>
          <fpage>2323</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2014-10-567479</pub-id>
          <pub-id pub-id-type="pmid">25636338</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Asano</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Tatematsu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Oyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kitamura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasmablastic lymphoma of the elderly: a clinicopathological comparison with age-related Epstein-Barr virus-associated B cell lymphoproliferative disorder</article-title>
          <source>Histopathology</source>
          <year>2012</year>
          <volume>61</volume>
          <issue>6</issue>
          <fpage>1183</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2559.2012.04339.x</pub-id>
          <pub-id pub-id-type="pmid">22958176</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horning</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>The natural history of initially untreated low-grade non-Hodgkin&#x2019;s lymphoma</article-title>
          <source>N. Engl. J. Med.</source>
          <year>1984</year>
          <volume>311</volume>
          <issue>23</issue>
          <fpage>1471</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM198412063112303</pub-id>
          <pub-id pub-id-type="pmid">6548796</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krikorian</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Portlock</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Cooney</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous regression of non-Hodgkin&#x2019;s lymphoma: a report of nine cases</article-title>
          <source>Cancer</source>
          <year>1980</year>
          <volume>46</volume>
          <issue>9</issue>
          <fpage>2093</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1002/1097-0142(19801101)46:9&lt;2093::AID-CNCR2820460931&gt;3.0.CO;2-4</pub-id>
          <pub-id pub-id-type="pmid">7427915</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abe</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ogawa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maruyama</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nakamura</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Abe</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous regression of diffuse large B-cell lymphoma harbouring Epstein-Barr virus: a case report and review of the literature</article-title>
          <source>J. Clin. Exp. Hematop.</source>
          <year>2007</year>
          <volume>47</volume>
          <issue>1</issue>
          <fpage>23</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.3960/jslrt.47.23</pub-id>
          <pub-id pub-id-type="pmid">17510535</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ichikawa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Arakawa</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kiyasu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Miyoshi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Niino</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression</article-title>
          <source>Eur. J. Haematol</source>
          <year>2013</year>
          <volume>91</volume>
          <issue>1</issue>
          <fpage>20</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1111/ejh.12116</pub-id>
          <pub-id pub-id-type="pmid">23560463</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dojcinov</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Venkataraman</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Raffeld</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pittaluga</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
          </person-group>
          <article-title>EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression</article-title>
          <source>Am. J. Surg. Pathol.</source>
          <year>2010</year>
          <volume>34</volume>
          <issue>3</issue>
          <fpage>405</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1097/PAS.0b013e3181cf8622</pub-id>
          <pub-id pub-id-type="pmid">20154586</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oyama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ichimura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Suzumiya</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ohshima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yatabe</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients</article-title>
          <source>Am. J. Surg. Pathol.</source>
          <year>2003</year>
          <volume>27</volume>
          <issue>1</issue>
          <fpage>16</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="doi">10.1097/00000478-200301000-00003</pub-id>
          <pub-id pub-id-type="pmid">12502924</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Armstrong</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bradrick</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>YC</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report</article-title>
          <source>J. Oral Maxillofac. Surg.</source>
          <year>2007</year>
          <volume>65</volume>
          <issue>7</issue>
          <fpage>1361</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1016/j.joms.2005.12.039</pub-id>
          <pub-id pub-id-type="pmid">17577503</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nasta</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Carrum</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Shahab</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Hanania</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Udden</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy</article-title>
          <source>Leuk Lymphoma</source>
          <year>2002</year>
          <volume>43</volume>
          <issue>2</issue>
          <fpage>423</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1080/10428190290006260</pub-id>
          <pub-id pub-id-type="pmid">11999580</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garc&#xED;a-Noblejas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Velasco</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cannata-Ortiz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Arranz</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous regression of immunodeficiency associated plasmablastic lymphoma related to methotrexate after decrease of dosage</article-title>
          <source>Med Clin (Barc)</source>
          <year>2013</year>
          <volume>140</volume>
          <issue>12</issue>
          <fpage>569</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1016/j.medcli.2012.10.001</pub-id>
          <pub-id pub-id-type="pmid">23177304</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
